ストックスクリーナーアプリを入手
3.50
5.42%
0.18
プレマーケット:
3.70
0.20
+5.71%
前日終値:
$3.32
開ける：
$3.08
24時間の取引高:
441.45K
Relative Volume:
0.41
時価総額：
$7.50M
収益：
$743.00K
当期純損益:
$-7.63M
株価収益率:
-0.2811
EPS:
-12.4498
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+20.27%
1か月 パフォーマンス:
+14.01%
6か月 パフォーマンス:
-57.93%
1年 パフォーマンス:
-84.78%
1日の値動き範囲:
$3.08
$3.90
1週間の範囲:
$2.83
$4.08
52週間の値動き範囲:
$2.83
$23.40
Can-Fite Biopharma Ltd ADR Stock (CANF) Company Profile
名前
Can-Fite Biopharma Ltd ADR
セクター
電話
972 3 924 1114
住所
10 Bareket Street, Kiryat Matalon PO Box 7537, Petah-Tikva
Compare CANF vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CANF
Can-Fite Biopharma Ltd ADR
|
3.50 | 7.50M | 743.00K | -7.63M | 0 | -12.45 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Can-Fite Biopharma Ltd ADR Stock (CANF) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2017-08-11 | 開始されました | Maxim Group | Buy |
| 2016-10-19 | 再開されました | ROTH Capital | Buy |
| 2016-08-29 | 再開されました | Rodman & Renshaw | Buy |
| 2015-11-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2015-03-31 | 繰り返されました | H.C. Wainwright | Buy |
| 2015-03-30 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2014-12-29 | 繰り返されました | ROTH Capital | Buy |
| 2014-11-18 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Can-Fite Biopharma Ltd ADR (CANF) 最新ニュース
Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months - ChartMill
CANF Ownership | CAN FITE BIOPHARMA LTD-ADR (NYSEARCA:CANF) - ChartMill
Can Fite Biopharma Ltd ADR (CANF) - Minichart
The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight - GlobeNewswire Inc.
CANF Stock Price, Quote & Chart | CAN FITE BIOPHARMA LTD-ADR (NYSEARCA:CANF) - ChartMill
Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026 - ChartMill
Can-Fite BioPharma (CANF) outlines clinical pipeline, cash runway and key risks - Stock Titan
Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient - ChartMill
CANF Earnings History & Surprises | EPS & Revenue Results | CAN FITE BIOPHARMA LTD-ADR (NYSEARCA:CANF) - ChartMill
Can-Fite receives Israeli patent for obesity treatment use - Investing.com
Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance - Sahm
12 Health Care Stocks Moving In Wednesday's After-Market Session - Sahm
CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data - Finviz
Can-Fite BioPharma raises $4M through warrant exercise - Investing.com
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds - ChartMill
Gapping stocks in Wednesday's session - ChartMill
Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy - ChartMill
Can Fite Biopharma stock rises after patient success with liver treatment - Investing.com
Can-Fite BioPharma schedules special shareholder meeting as NYSE American issues non-compliance notice - Investing.com
Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson - Sahm
Published on: 2026-01-10 23:44:28 - ulpravda.ru
Why Aptevo Therapeutics Shares Are Trading Lower By Around 38%? Here Are Other Stocks Moving In Friday's Mid-Day Session - Benzinga
Can Fite Biopharma stock soars on Brazil patent grant for sexual dysfunction - Investing.com
Can Fite Biopharma stock soars on Brazil patent grant for sexual dysfunction By Investing.com - Investing.com South Africa
Can-Fite Biopharma Ltd Sponsored ADR (Israel) (NYSE:CANF) Stock Quote - FinancialContent
Can-Fite BioPharma stock rating downgraded to Hold by D. Boral Capital - Investing.com South Africa
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Sahm
Why Multi Ways Holdings Shares Are Trading Higher By Around 60%; Here Are 20 Stocks Moving Premarket - Sahm
UiPath, Ramaco Resources And 3 Stocks To Watch Heading Into Wednesday - Sahm
NYSE AMEX Composite Index (XAX) - Investing.com Canada
Can Fite Biopharma stock tumbles after announcing 1-for-3,000 reverse split By Investing.com - Investing.com South Africa
Can Fite Biopharma stock tumbles after announcing 1-for-3,000 reverse split - Investing.com India
Can-Fite BioPharma announces 1-for-3,000 reverse stock split - Investing.com
Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change - Sahm
Can Can Fite Biopharma Ltd Sponsored ADR stock ride next bull market cycleMarket Rally & Community Verified Trade Signals - Улправда
EBITDA per share of Can-Fite BioPharma Ltd. Sponsored ADR – AMEX:CANF - TradingView — Track All Markets
AST SpaceMobile Inc (ASTS) can make a big difference with a little luck - setenews.com
Can Can Fite Biopharma Ltd Sponsored ADR stock survive global slowdown2025 Price Momentum & AI Based Trade Execution Alerts - Newser
Will Can Fite Biopharma Ltd Sponsored ADR stock see insider accumulation2025 Fundamental Recap & Daily Technical Forecast Reports - Newser
Can Can Fite Biopharma Ltd Sponsored ADR stock sustain breakout momentum2025 Investor Takeaways & Expert Approved Momentum Ideas - Newser
Can Can Fite Biopharma Ltd Sponsored ADR stock test all time highsMarket Performance Report & Free Expert Approved Momentum Trade Ideas - Newser
How big funds are accumulating Can Fite Biopharma Ltd Sponsored ADR stockDividend Hike & AI Enhanced Trade Execution Alerts - Newser
Is Can Fite Biopharma Ltd Sponsored ADR stock positioned for secular growth2025 Key Lessons & Growth Focused Entry Reports - Newser
Can Can Fite Biopharma Ltd Sponsored ADR stock deliver double digit returnsJuly 2025 Short Interest & Fast Moving Stock Watchlists - Newser
An analyst sees good growth prospects for Can-Fite Biopharma Ltd ADR (CANF) - Setenews
Can-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference - Sahm
12 Health Care Stocks Moving In Monday's After-Market Session - Sahm
You might want to take a look at Pasithea Therapeutics Corp (KTTA) now - Setenews
Can-Fite to Advance New Veterinary Partnership Opportunities for Namodenoson at the BioFIT 2025 Conference - The Manila Times
Can-Fite Biopharma Ltd ADR (CANF) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):